Workflow
连续血糖监测仪(CGM)
icon
Search documents
美敦力任命新高管!糖尿病子公司上市准备提速
思宇MedTech· 2025-07-10 10:13
# 关于Chad Spooner 2025年5月,美敦力宣布计划将其糖尿病业务分拆为一家独立的、公开上市的公司,预计在 18个月内 完成分 离。MiniMed将继承美敦力在糖尿病管理领域的创新传统, 专注于提供完整的胰岛素管理系统,包括自动胰 岛素泵、连续血糖监测仪(CGM)和智能胰岛素笔等产品 。 2025年7月8日, Medtronic(美敦力) 宣布, Chad Spooner将于2025年7月14日起正式出任其糖尿病业 务部门 MiniMed 的首席财务官(CFO) 。此次任命正值Medtronic计划将糖尿病业务分拆为一家独立上市公 司之际,旨在为该业务板块的独立运营和未来发展奠定财务与战略基础。 Chad Spooner 拥有超过25年的财务领导经验,横跨医疗、消费品和工业领域,具备丰富的企业转型、财务 战略和资本市场运作经验。以下是其关键职业经历: 高管评价 BIC集团(BIC Group)CFO :在加入Medtronic之前,Spooner担任全球消费品公司BIC的 首席财务 官 ,负责全球财务战略、投资者关系及企业并购事务。 Tenex Capital Management :他曾联合创办 ...
【美好医疗(301363.SZ)】业绩有望逐步改善,期待新业务拓展潜力——更新点评(王明瑞/吴佳青)
光大证券研究· 2025-06-27 14:02
Core Viewpoint - The company anticipates gradual improvement in performance in Q2 2025 and the second half of the year, following the end of inventory destocking by downstream customers in the home respiratory device component sector [3]. Group 1: Home Respiratory Devices and Cochlear Implants - The company's core business involves the development, manufacturing, and sales of home respiratory devices and cochlear implant components [3]. - In 2024, the company expects a return to normal growth rates for home respiratory device component orders, supported by the Malaysian base potentially avoiding tariff risks, which is expected to drive long-term revenue growth [3]. - Revenue from cochlear implant components is showing steady growth, and new product component revenues are rapidly increasing, indicating effective diversification in business segments [3]. - Due to the impact of the Spring Festival on Q1 2025, revenue growth has slowed compared to the full year of 2024, but performance is expected to improve gradually as order deliveries resume [3]. Group 2: Blood Glucose Management and Production Expansion - The company has made breakthroughs in core technologies such as precision molds and liquid silicone, focusing on products like disposable injection pens, continuous glucose monitoring (CGM) devices, and insulin patch pumps [4]. - Collaborations with global medical device leaders are ongoing in the fields of blood glucose management, IVD diagnostics, and cardiovascular devices [4]. - A fully automated production project for insulin injection pens developed for international clients has achieved large-scale production in 2024 [4]. - The company has completed the core R&D work for its self-designed "Beautiful Pen," which includes three major technology directions [4]. - The Malaysian production base has successfully completed the first two phases of capacity construction, with the third phase expected to be operational by the end of 2025 [4]. Group 3: Stock Incentive Plan - The company has announced a stock incentive plan for 2025, granting a total of 5 million shares to no more than 304 core employees, representing 1.23% of the total share capital [5]. - The performance assessment for the stock incentive plan is based on revenue or net profit for 2023, with target growth rates for 2025-2027 set at no less than 56.25%, 95.31%, and 144.14% respectively [5]. - The triggering growth rates for 2025-2027 are set at no less than 44.00%, 72.80%, and 107.36% respectively, reflecting the company's confidence in long-term growth [5].